Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Receivables (2022 - 2025)

Historic Receivables for Voyager Therapeutics (VYGR) over the last 4 years, with Q3 2025 value amounting to $4.0 million.

  • Voyager Therapeutics' Receivables fell 7947.43% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 7947.43%. This contributed to the annual value of $2.2 million for FY2024, which is 9738.89% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Receivables stood at $4.0 million, which was down 7947.43% from $2.5 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Receivables high stood at $83.5 million for Q4 2023, and its period low was $2.1 million during Q1 2025.
  • Over the past 4 years, Voyager Therapeutics' median Receivables value was $3.7 million (recorded in 2024), while the average stood at $15.6 million.
  • In the last 5 years, Voyager Therapeutics' Receivables crashed by 9738.89% in 2024 and then crashed by 2233.16% in 2025.
  • Over the past 4 years, Voyager Therapeutics' Receivables (Quarter) stood at $10.2 million in 2022, then soared by 716.54% to $83.5 million in 2023, then tumbled by 97.39% to $2.2 million in 2024, then soared by 85.18% to $4.0 million in 2025.
  • Its Receivables was $4.0 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.1 million in Q1 2025.